^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) + ERAS-601 (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ERAS-601, a potent inhibitor of SHP2, synergistically enhances the activity of a FLT3 inhibitor, gilteritinib, in FLT3-mutated AML tumor models
Published date:
03/09/2022
Excerpt:
Here, we explored the combination of gilteritinib with ERAS-601 in FLT3 mutated AML nonclinical models...The combination of ERAS-601 with gilteritinib achieves a more durable tumor growth inhibition than the respective gilteritinib and ERAS-601 monotherapies in vivo. These preclinical data support the clinical development of ERAS-601 in combination with gilteritinib in FLT3-altered AML.
